(REGMY), Quotes and News Summary


RemeGen Co Ltd is a commercial-ready biopharmaceutical company committed to the discovery, development, and commercialization of innovative and differentiated biologics for the treatment of autoimmune, oncology and ophthalmic diseases with unmet medical needs in China and globally. The company's drug candidates include Telitacicept (RC18); Disitamab Vedotin (RC48); RC88; RC98; RC108; RC118; RC138; RC148; RC158; and RC28.